Rossella Graffeo1,2, Luca Livraghi3, Olivia Pagani4, Aron Goldhirsch5, Ann H Partridge6, Judy E Garber6. 1. Department of Medical Oncology, European Institute of Oncology, Milan, Italy. rossella.graffeogalbiati@eoc.ch. 2. Institute of Oncology of Southern Switzerland (IOSI) and Breast Unit of Southern Switzerland (CSSI), Bellinzona, Switzerland. rossella.graffeogalbiati@eoc.ch. 3. Medical Oncology Unit ASST Papa Giovanni XXIII, Bergamo, Italy. 4. Institute of Oncology of Southern Switzerland (IOSI) and Breast Unit of Southern Switzerland (CSSI), Bellinzona, Switzerland. 5. Department of Medical Oncology, European Institute of Oncology, Milan, Italy. 6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
PURPOSE: Genetic evaluation is increasingly becoming an integral part of the management of women with newly diagnosed breast and ovarian cancer (OC), and of individuals at high risk for these diseases. Genetic counseling and testing have been incorporated into oncological care to help and complete management and treatment strategies. Risk assessment and early detection strategies in individuals with BRCA1/2 mutations and with Lynch syndrome have been quite extensively studied, whereas much less is known about the management of mutation carriers with less common high-penetrance cancer susceptibility genes (PTEN, TP53, STK11, CDH1), and particularly those who carry mutations in moderate-penetrance genes (e.g., PALB2, CHEK2, ATM, NF1, RAD51C, RAD51D, BRIP1). METHODS: The latter patient groups represent important ongoing research opportunities to enable informed counseling about appropriate clinical management. CONCLUSION: We summarize the current guidelines for the management of high and moderate-penetrance mutations for breast and OC susceptibility. Continuous updating of guidelines for proper clinical management of these individuals is ongoing because of rapid advances in technology and knowledge in this field. Thus, we exhort the use of multigene panels for the assessment of cancer risk beyond the classic predisposition syndromes as a new standard of care in cancer genetics. We further support an increase of genetic counselors in Europe and use of their expertise to support genetic testing in specialist multidisciplinary teams.
PURPOSE: Genetic evaluation is increasingly becoming an integral part of the management of women with newly diagnosed breast and ovarian cancer (OC), and of individuals at high risk for these diseases. Genetic counseling and testing have been incorporated into oncological care to help and complete management and treatment strategies. Risk assessment and early detection strategies in individuals with BRCA1/2 mutations and with Lynch syndrome have been quite extensively studied, whereas much less is known about the management of mutation carriers with less common high-penetrance cancer susceptibility genes (PTEN, TP53, STK11, CDH1), and particularly those who carry mutations in moderate-penetrance genes (e.g., PALB2, CHEK2, ATM, NF1, RAD51C, RAD51D, BRIP1). METHODS: The latter patient groups represent important ongoing research opportunities to enable informed counseling about appropriate clinical management. CONCLUSION: We summarize the current guidelines for the management of high and moderate-penetrance mutations for breast and OC susceptibility. Continuous updating of guidelines for proper clinical management of these individuals is ongoing because of rapid advances in technology and knowledge in this field. Thus, we exhort the use of multigene panels for the assessment of cancer risk beyond the classic predisposition syndromes as a new standard of care in cancer genetics. We further support an increase of genetic counselors in Europe and use of their expertise to support genetic testing in specialist multidisciplinary teams.
Entities:
Keywords:
BRCA; Breast and ovarian cancer; Cancer genetic counseling; Genetic counselors; Multiple-gene panel testing; Surveillance
Authors: Yuan Chun Ding; Aaron W Adamson; Linda Steele; Adam M Bailis; Esther M John; Gail Tomlinson; Susan L Neuhausen Journal: Fam Cancer Date: 2018-04 Impact factor: 2.375
Authors: Margaret Waltz; Anya E R Prince; Julianne M O'Daniel; Ann Katherine M Foreman; Bradford C Powell; Jonathan S Berg Journal: J Genet Couns Date: 2020-01-22 Impact factor: 2.537
Authors: Antônio Luiz Frasson; Martina Lichtenfels; Alessandra Anton Borba de Souza; Betina Vollbrecht; Ana Beatriz Falcone; Mônica Adriana Rodriguez Martinez Frasson; Fernanda Barbosa Journal: Breast Cancer Res Treat Date: 2020-03-25 Impact factor: 4.872
Authors: Rachel A Pozzar; Fangxin Hong; Niya Xiong; Jill E Stopfer; Manan M Nayak; Meghan Underhill-Blazey Journal: Fam Cancer Date: 2021-03-10 Impact factor: 2.375